SLC5A2 and chronic kidney disease: Our single-center prospective study contributes a nuanced view of post-CABG rehabilitation outcomes in patients with/without T2DM and with/without CKD, pathologies for which an SGLT2 inhibitor has been proven beneficial during a cardiovascular rehabilitation program.